Clinical

Bruce A. Feinberg, DO, of Cardinal Health Specialty Solutions, leads a panel discussion on how far randomized clinical trials have come, how they could be better, and how using real-world evidence could make research more representative of the population.

As the pandemic wore on, fewer patients with sickle cell disease who did contract COVID-19 needed to be hospitalized.

David Yeomans, PhD, associate professor of anesthesiology, perioperative, and pain medicine at Stanford University School of Medicine, discusses the potential therapeutic use of intranasal oxytocin spray for menstrual-related migraine.

Under the expanded FDA label, up to 1.8 million individuals in the United States could be eligible for sacubitril/valsartan, and up to 180,000 worsening heart failure (HF) events could be prevented or postponed.

Drawing a clearer picture of the relationship between pulmonary artery involvement (PAI) in Takayasu arteritis (TAK), researchers have published data on the clinical features of TAK with PAI.

Among the issues presented in patients with Turner syndrome, short stature is one of the most prominent, and investigators from Korea investigated the effects of a new recombinant growth hormone among this population.

Research presented at the Revolutionizing Atopic Dermatitis (RAD) Virtual Conference said dupilumab (Dupixent) is an effective and safe therapeutic option in adults, adolescents aged 6 to 11 years, and young children aged 6 months to 5 years with moderate-to-severe atopic dermatitis.

There are 2 such vaccines now in use in the United States; the Pfizer-BioNTech vaccine is fully approved for the first 2 doses for those 16 and older, and the Moderna vaccine has an emergency use authorization for those 18 and older.

In a study published in our December issue, researchers analyzed how prescribing of the newly approved heart failure drug sacubitril/valsartan diffused across the nation.

Stacy Courtnay is the community network chair for the Arthritis Foundation in Atlanta highlights a report that discusses how understanding patient experiences in RA can shift questions researchers ask.

Final results from the MASTER trial presented at this year’s 63rd Annual American Society of Hematology Annual Meeting and Exposition bear out the benefits of quadruplet therapy and using minimal residual disease (MRD) status among patients with newly diagnosed multiple myeloma (MM).

A total of 92 gene variants were sequenced, 41 of which were novel.

The patient experienced lasting improvement when belimumab was added to her regimen after 2 years.

The insulin delivery system was linked with a reduction in hypoglycemia among adults and a decrease in hyperglycemia in both adults and children.

Researchers examined the safety and efficacy of erenumab in patients with episodic migraine for whom up to 4 previous treatments have been ineffective.

Two doses of the Moderna COVID-19 vaccine have reduced efficacy against the Omicron variant; a federal appeals court reinstates the Biden administration’s health care worker vaccine mandate in 26 states; a new combination therapy may reduce breast cancer progression.

Pulmonary arterial hypertension is a rare form of pulmonary hypertension that poses diagnostic challenges and often comes with a delayed diagnosis.

Subcutaneous (sub-Q) administration of isatuximab plus pomalidomide may provide survival advantages for patients with relapsed and refractory multiple myeloma, making it another treatment option for this patient group.

Investigators said pathologic complete response was higher with a molecularly selected subgroup of patients with early-stage breast cancer treated with a nonchemotherapy combination that included a trastuzumab biosimilar.

Results of a secondary analysis indicate anxiety, depression, physical quality of life (QOL), and sexual function in obese infertile woman with polycystic ovary syndrome (PCOS) seem to be more related to obesity rather than PCOS status.

In India, incidence of the deadly fungal infection grew throughout 2021, while supply chain shortages inhibited optimal treatment for each patient.

Bhavesh Shah, PharmD, and Mark Lebwohl, MD, elaborate on treatment effectiveness in patients with both psoriasis and metabolic syndrome.

Drs Lebwohl and Groves discuss patients with psoriasis and the increased risk they have for also being diagnosed with metabolic syndrome.

An abstract presented at the 63rd Annual American Society of Hematology Annual Meeting and Exposition shows that although daratumumab use in multiple myeloma holds great promise, challenges remain in the use of clinical pathways for treatment direction with the monoclonal antibody—which the investigators say may also present opportunities for change.

John Burke, MD, hematologist, Rocky Mountain Cancer Centers, discussed findings of the late-breaking abstract session POLARIX presented at ASH 2021, which compared pola-R-CHP with standard-of-care R-CHOP in patients with previously untreated DLBCL.

Results presented at the 63rd Annual American Society of Hematology Meeting showed that using polatuzumab vedotin instead of vincristine in R-CHOP improved progression-free survival in patients with newly diagnosed diffuse large B-cell lymphoma.

David Yeomans, PhD, associate professor of anesthesiology, perioperative, and pain medicine at Stanford University School of Medicine, outlines potential mechanisms underlying menstrual-related migraine.

Sattva S. Neelapu, MD, professor and deputy department chair in the Department of Lymphoma/Myeloma in the Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center, discusses findings of the ZUMA-12 study examining axicabtagene ciloleucel (axi-cel) as a first-line treatment option for high-risk patients with large B-cell lymphoma.